Official Journal

We inform you that the way of access to TAD Online was changed. First, please visit our new website (URL:, and log in website. And please go to Member's Page, click the link of "Online TAD". You can access to TAD Online if your payment was completed.

We are now in the process of sending username and password for the members whose payment was completed. But, if you already got password by yourself, please use it.

Therapeutic Apheresis and Dialysis (official journal) has been chosen by the National Library of Medicine for Indexing in Index Medicus and MedLine. All issues starting with Volume 1, Number 1 have been indexed and available on MedLine already.

Published bi-monthly, Therapeutic Apheresis and Dialysis recognises the value of apheresis treatment in many fields of medicine. Publishing content spanning medicine, biology, biophysics, and engineering with a particular emphasis on how they converge in the development of new technologies and treatments resulting in improved patient outcomes.The Journal is published on behalf of International Society for Apheresis, The Japanese Society for Apheresis and The Japanese Society for Dialysis Therapy. Manuscripts can be submitted online via Manuscript Central.

Go to Online Journal Instructions For Authors

Editor's Choice of Issue 3 (Vol.17: 2013)

Clinical Practice Guideline for the Management of Chronic Kidney Disease-Mineral and Bone Disorder

Volume 17, Issue 3, pages 247-288, June 2013

Masafumi Fukagawa, Keitaro Yokoyama, Fumihiko Koiwa, Masatomo Taniguchi, Tetsuo Shoji, Junichiro James Kazama, Hirotaka Komaba, Ryoichi Ando, Takatoshi Kakuta, Hideki Fujii, Msasaaki Nakayama, Yugo Shibagaki, Seiji Fukumoto, Naohiko Fujii, Motoshi Hattori, Akira Ashida, Kunitoshi Iseki, Takashi Shigematsu, Yusuke Tsukamoto, Yoshiharu Tsubakihara, Tadashi Tomo, Hideki Hirakata and Tadao Akizawa, CKD-MBD Guideline Working Group, Japanese Society for Dialysis Therapy

This GL is the updated one for all Japanese CKD-MBD patients. Previous GL has been applied only for dialysis patients, however recent GL is applicable for CKD patients before starting dialysis and post kidney transplantation as well. This GL recommends and suggests Japan specific treatment policy based on Japanese evidence. This GL is expected to be widely noticed by many scientists in this field.

Editor's Choice of Issue 1 (Vol.17: 2013)

Hepcidin is a Potential Regulator of Iron Status in Chronic Kidney Disease

Volume 17, Issue 1, pages 1–8, February 2013

Ken Tsuchiya and Kosaku Nitta

Hepcidin is a peptide that is primarily produced by the liver for iron homeostasis. It is a crucial mediator for iron absorption and mobilization, and plays a key role in the pathophysiology of anemia in the CKD patients. Now, serum hepcidin could be measured stably, and the measurement of hepcidin in CKD patients with and without dialysis is pointed out. The present article will review the latest data on the role of hepcidin and potential as a clinical biomarker and investigational treatments targeting for hepcidin.

Parathyroid Enlargement at Dialysis Initiation in Patients With Chronic Kidney Diseases

Volume 17, Issue 1, pages 24–29, February 2013

Kentaro Nakai, Hideki Fujii, Keiji Kono et al.

Figure 1

Figure 1. Comparison of serum phosphorus and corrected calcium levels in patients with or without enlarged parathyroid lands. In patients with serum phosphorus and calcium levels within the optimal range (serum phosphorus: 3.5–6.0 mg/dL; serum calcium: 8.4–10.0 mg/dL), eight patients had enlarged parathyroid glands (square), while 21 did not (circle).

It is well known that chronic kidney disease-mineral bone disorder (CKD-MBD) is associated with cardiovascular risk and mortality. However, the impact of its management before dialysis initiation on the presence of secondary hyperparathyroidism during chronic dialysis period remains unclear. We performed ultrasonography of parathyroid glands before and after dialysis initiation and investigated the association between management of CKD-MBD and the presence of enlarged parathyroid gland. The present study suggested that the presence of enlarged parathyroid gland at dialysis initiation predict the persistence of secondary hyperparathyroidism during chronic dialysis period and reflect needs for restrict management of CKD-MBD from pre-dialysis period.

Survey of the Effects of a Column for Adsorption of β2-Microglobulin in Patients With Dialysis-Related Amyloidosis in Japan

Volume 17, Issue 1, pages 40–47, February 2013

Fumitake Gejyo, Izumi Amano, Tetsuo Ando, et al.

This article will present the result of the first nationwide questionnaire survey on the therapeutic effect of Lixelle, a direct hemoperfusion column for adsorption of β2-microglobulin to treat dialysis-related amyloidosis conducted in Japan. The answers collected from 345 patients and their attending physicians suggested the effectiveness of Lixelle treatment to improve QOL of the patients and to prevent progression of dialysis-related amyloidosis.

Impact Factor

The 2012 Impact factor .....released on June, 2013.

it was 1.529.

TAD Early View

Articles that have been fully copy-edited and peer-reviewed are published online before the print edition of this journal is published.

Go to TAD Early View

Therapeutic Apheresis and Dialysis (official journal) has been chosen by the National Library of Medicine for Indexing in Index Medicus and MedLine. All issues starting with Volume 1, Number 1 have been indexed and available on MedLine already.

Go to TAD pubmed

Prof.Kurt Derfler informed that a special topic issue of the TRANSPLANT INTERNATIONAL now has been published and you can get the PDF version from Wiley Online Library(